Long Noncoding RNA MNX1-AS1 Knockdown Inhibits Cell Proliferation and Migration in Ovarian Cancer

Abstract

Long noncoding RNAs (lncRNAs) have recently emerged as pivotal regulators that govern fundamental biological processes and disease pathogenesis. LncRNA MNX1-AS1 has been reported to promote cell proliferation and invasion in gallbladder cancer, but its biological role and regulatory mechanism in ovarian cancer are poorly defined. In this study, it was found that higher expression of lncRNA MNX1-AS1 is closely associated with International Federation of Gynecology and Obstetrics stage and lymphatic metastasis in ovarian cancer patients. RNA interference (RNAi) to downregulate the expression of lncRNA MNX1-AS1 was used in the ovarian cancer cell lines, OVCA433 and SKOV-3. CCK-8, EdU staining, and colony formation assays was used to test the viability and proliferation ability of these cells. Wound healing and transwell migration assays were performed to determine the migration ability of the cells. Cell cycle progression and apoptotic assays were carried out using flow cytometry. These in vitro loss-of-function experiments revealed that downregulation of lncRNA MNX1-AS1 suppressed cell proliferation, colony formation, cell migration ability, induced cell cycle arrest at the G0/G1 phase, and promoted apoptosis. Furthermore, MNX1-AS1 knockdown altered the protein expressions of CDK4, cyclin D, Bax, and Bcl-2. These findings demonstrated for the first time that lncRNA MNX1-AS1 functions as an oncogene in ovarian cancer and could be a potential target for this disease.

Upregulated expression of MNX1-AS1 long noncoding RNA predicts poor prognosis in gastric cancer

“…In recent years, considerable effort has been made to identify mechanisms of lncRNAs in cancer initiation and progression [19]. Previous studies suggested that MNX1-AS1 lncRNA has an oncogenic role in ovarian cancer [17] and glioblastoma [18], however, the biological function and clinicopathological significance of MNX1-AS1 in GC have not been systematically investigated so far. In this study, we analyzed the expression of MNX1-AS1 in GC and adjacent non-tumor tissues in relation to clinicopathological features and 5-year OS of GC patients.…”

“…In patients with ovarian cancer, MNX1-AS1 expression is associated with the International Federation of Gynecology and Obstetrics (FIGO) stage, tumor grade, distant metastasis and poor OS, which suggests it could be used as a prognostic marker [16]. Moreover, downregulation of MNX1-AS1 by RNA interference suppresses cell proliferation, colony formation, cell migration ability and promotes apoptosis in ovarian cancer cell lines, indicating that MNX1-AS1 has an oncogenic role in ovarian cancer [17]. Similarly, Gao et al [18] showed that MNX-AS1 promotes glioblastoma cell proliferation, invasion and migration, by suppressing miR-4443.…”

Upregulation of hsa_circ_0007874 suppresses the progression of ovarian cancer by regulating the miR‐760/SOCS3 pathway

“…Ovarian cancer (OVA) is a fatal and popular malignancy among women worldwide, accounting for 5%‐6% of cancer‐related deaths . In 2017, it was estimated that 22 500 patients were diagnosed with OVA and 14 100 patients died from the disease in the United States . Because of the vagueness of symptoms and the lack of early detection tests, 70%‐75% of OVA patients are at advanced stages when first diagnosed .…”

“…1,2 In 2017, it was estimated that 22 500 patients were diagnosed with OVA and 14 100 patients died from the disease in the United States. 3,4 Because of the vagueness of symptoms and the lack of early detection tests, 70%-75% of OVA patients are at advanced stages when first diagnosed. 5 The current standard therapeutic strategy for OVA is surgery combined with chemotherapy.…”

The prognostic utility and clinical outcomes of MNX1-AS1 expression in cancers: a systematic review and meta-analysis

“…Several studies for the first time provided that MNX1-AS1 has a sponge adsorption effect on miR-6785-5p, thereby up-regulating the expression of BCL2, and overexpression of MNX1-AS1 might facilitate the proliferation, migration and invasion of gastric cancer cells [8][9][10]. Knockdown of MNX1-AS1 might affect the expression of CDK4, cyclin D, Bax, and Bcl-2, which may inhibit proliferation and migration capabilities, and promote apoptosis of ovarian cancer cells [11]. In recent years, some studies have reported that MNX1-AS1 is upregulated in tissues of various cancers, including: hepatocellular carcinoma [12], bladder Cancer [13], esophageal squamous cell carcinoma [14,15], lung cancer [16], prostate cancer [17], cervical cancer [18], etc.…”